NEW YORK, December 15, 2016 /PRNewswire/ --

After November's US elections, 28 states plus the District of Columbia allowed the usage of medical marijuana even as federal law prohibits it. Since then, there has been a rapid acceptance of cannabis by consumers for both medicinal and recreational purposes and the global legal marijuana market is poised to grow to $140.5 billion in 2020 from $28.8 billion in 2015, according to global marketing firm Technavio. Medicine Man Technologies Inc. (OTC: MDCL), Medical Marijuana Inc., GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Cannabis Sativa Inc. (OTC: CBDS)

Matt Karnes of Greenwave Advisors, a research and financial analysis company of the emerging legalized marijuana industry, is very optimistic about the growth of the cannabidiol market, which is used for medical purposes. "In terms of the cannabidiol market size, I estimate an almost $3 billion market by 2021. Right now there are 15 states that allow cannabidiol only - this is in addition to the 28 states plus District of Columbia that have legalized medical marijuana," he added.

Provider of consulting services that covers all aspects of cannabis cultivations, Medicine Man Technologies Inc. (OTCQB: MDCL) implements a risk averse growing environment, applying high-tech indoor cannabis cultivation equipment and engages in medical and adult use dispensaries. The company is moving ahead to bring the benefits of mutual experience and technologies to a market engaged by marijuana growers in need of augmented productivity. During the month of August, Medicine Man had acquired Pono Publications Inc. and Success Nutrients Inc. in order to include the Three A Light™ cultivation publication that sold more than 800 copies.

Three A Light™ has made plans to release its 'Professional Grade' guide that will be sold to Medicine Man Technologies licensed grade clients, by the end of the year. Recently, Medicine Man has negotiated with Pono Publications and Success Nutrients to enter into an Interim Products and Services Support that would have both business to better engage with one another while the final details of the acquisition are worked out. The Company also announced that they are working on acquiring Capital G (Funk Sack and Odor No), having to build out its brand warehouse concept.

The Company has recently launched a new service called "Cultivation MAX". Cultivation Max provides cultivation advisory services to current operators who wants to increase their yields through deployment of its collective efficiencies. "We anticipate revenues related to this new deployment to include design fees as well as income derived by formula arising from the anticipated improvement experienced in our client's cultivation practices. While no specific assurances can be provided, we believe this future income stream may be substantial based upon current performance levels noted in the cannabis cultivation landscape within states allowing for access of such related products," stated Medicine Man Technologies.

GW Pharmaceuticals (NASDAQ: GWPH) is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company's primary focus is on disorders of the central nervous system including epilepsy. Their leading cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol, or cannabidiol, which is in development for the treatment of a number of rare childhood-onset epilepsy disorders. Its second cannabinoid medicine is the Sativex®, for the treatment of multiple sclerosis spasticity.

Clinical-stage biopharmaceutical company, Cara Therapeutics Inc. (NASDAQ: CARA) focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. Cara has recently complete the enrollment of 8-week multi-dose phase of adaptive trial of I.V. CR845 in Uremic Pruritus. Uremic pruritus, or more fittingly called the "chronic kidney disease-associated pruritus", is a chronic itching that occurs in patients with advanced or end-stage renal disease. It is acknowledged to affect roughly 20-50 percent of patients with renal failure and will cause long-term pain and suffering.

Clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is currently in developments of therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol, a non-psychoactive cannabinoid, and tetrahydrocannabinol. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. Zynerba's cannabidiol gel, ZYN002, is the first and only synthetic cannabidiol formulated as a patent protected permeation-enhanced gel for adult refractory epilepsy patients with focal seizures.

Cannabis Sativa Inc. (OTCQB: CBDS) cultivates and markets natural cannabis products. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. The Company is developing a third strain of cannabis plant named CT22. The Company also conducts its operations through its subsidiary, Wild Earth Naturals Incorporated. Wild Earth is an herbal skin care products formulation and marketing company that plans to target the natural healthcare products market in the United States and abroad. It offers Go Deep, Go Deep EXTRA, Face Garden, Body Garden and Lip Garden.

Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. Financialbuzz.com has been compensated three thousand dollars for financial news dissemination and pr services by a third party non affiliate for medicine man technologies inc. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:

Media Contact: info@financialbuzz.com, +1-877-601-187

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com